AzTrials
AzTrials

Multiple Chronic Conditions (Unspecified)NCT07761676

The Cohort Construction Project of Peking University Third Hospital

An observational study of Multiple Chronic Conditions (Unspecified) and Large-scale Health Examination Cohort, run by Peking University Third Hospital at 1 site in China.

Recruiting

Looking for participants now. Contact the study team or a site below to ask about taking part.

Sites and contacts
Official record
Search all trials

Trial summary

The specific construction goals for this period include enrolling 100,000 individuals for dynamic follow-up, perfecting the biobank by collecting biological samples from 20,000 individuals, and gathering health questionnaire information from 30,000 people. Read more about this study

Who is it for?
Ages 18 years and older
What is being tested?
observational study
How many people
100,000 participants
Where
1 siteChina
Study dates
21 Feb 2025to 31 Dec 2027
How long will I take part?
3 Years
Phase
Observational
Are there results?
Not yet: the study is under way

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Study population: The study population consists of individuals who voluntarily undergo health examinations at the Physical Examination Center of Peking University Third Hospital. Participants are recruited from group health examination populations (including employees from functional community units such as government agencies, schools, and enterprises) who have undergone at least two consecutive health examinations at the center. The study includes both retrospective and prospective participants, with long-term follow-up and biospecimen collection (serum) stored in the hospital's biobank.

Who may be able to join

  • Age ≥ 18 years. Participants must be from group health examination populations who have undergone at least two consecutive health examinations at our Physical Examination Center.

Who cannot join

  • Failure to provide informed consent. Incomplete data, including incomplete health examination self-administered questionnaires.

Trial locations and contacts

1 site in 1 country. Contact the study team or a site near you to ask about taking part.

Liyuan Tao, PhD contact

+86 13581552613

tendytly@163.com

China1 site, 1 recruiting
  • Physical Examination Center, Peking University Third Hospital

    Beijing, Beijing Municipality, 100191

    Peng Wang, MMed, +86 13601015655, bysywp@126.com

    Liyuan Tao, PhD, +86 13581552613, tendytly@163.com

    Recruiting

Other trials in China

About this study

The specific construction goals for this period include enrolling 100,000 individuals for dynamic follow-up, perfecting the biobank by collecting biological samples from 20,000 individuals, and gathering health questionnaire information from 30,000 people. The near-term goals emphasize the use of health check-up data combined with advanced artificial intelligence technologies to build disease prediction models and explore the association between retinal photographs and overall health status, which will assist in early screening and personalized interventions for high-risk populations. The medium- to long-term goals focus on biological age-related research, utilizing telomere length and multi-omics technologies to assess the differences between biological age and chronological age and analyze their key influencing factors. Data collection will be implemented through the health check-up centers of multiple campuses of PUTH.

Read the detailed description

The construction of a health check-up follow-up cohort holds significant importance for public health research. Since its establishment in 2022, the Health Check-up Cohort of Peking University Third Hospital (PUTH) has been operational for three years. The cohort features comprehensive health check-up indicators, including physical examination, biochemical tests, cancer screening, and 13 other major categories of indicators. It is equipped with a robust data management system and collaborates with the Clinical Epidemiology Research Center and the biobank. A multidimensional database has been established, covering health check-up information, health questionnaires, and biological samples of the study subjects. The cohort adopts a bidirectional study design, with the retrospective part covering individuals who underwent health check-ups since 2011 and the prospective part continuously enrolling subjects since 2022. As of 2023, the PUTH Health Check-up Cohort has collected health check-up data from over 80,000 study subjects, with the longest follow-up duration reaching 12 years, forming a longitudinal health database with continuous follow-up.

The cohort construction project has achieved favorable research outcomes, with a total of 14 academic papers published, including 8 SCI papers, and two invention patents granted. In addition, the cohort has collaborated with clinical departments within the hospital and has previously received funding from both internal and external horizontal and vertical projects. The primary focus has been on conducting research on medical reference value ranges and disease prevention and control among the health check-up cohort population. Building on the solid foundation of previous work, the cohort study will continue to optimize and expand, aiming to align with international large-scale cohorts by constructing a health check-up cohort with a large sample size, long follow-up duration, and high follow-up density.

The specific construction goals for this period include enrolling 100,000 individuals for dynamic follow-up, perfecting the biobank by collecting biological samples from 20,000 individuals, and gathering health questionnaire information from 30,000 people. The near-term goals emphasize the use of health check-up data combined with advanced artificial intelligence technologies to build disease prediction models and explore the association between retinal photographs and overall health status, which will assist in early screening and personalized interventions for high-risk populations. The medium- to long-term goals focus on biological age-related research, utilizing telomere length and multi-omics technologies to assess the differences between biological age and chronological age and analyze their key influencing factors. Data collection will be implemented through the health check-up centers of multiple campuses of PUTH.

The construction of this health check-up cohort provides a solid data foundation for the prevention of chronic diseases, individualized health management, and research on healthy aging. Through long-term follow-up and large-scale data collection, it can reveal disease risk factors, develop early prediction models, and in combination with biomarkers and multi-omics technologies, it helps explore the relationship between biological age and health status, promoting the development of precision medicine and the optimization of public health policies.

Being tested
observational study
Keywords
Health Management, Health Check-up, Cohort Study
Medical subject headings
Multiple Chronic Conditions

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • observational studyOther

    This is an observational study designed to investigate the mental health status and its influencing factors in the general physical examination population. No interventions are assigned to participants based on a protocol.

Study groups in NCT07761676
Study groupRoleWhat they receive
Functional Community Health Examination CohortThis cohort consists of employees from functional community units (such as government agencies, schools, and enterprises) who undergo regular health examinations at the Physical Examination Center of Peking University Third Hospital. The cohort integrates both retrospective and prospective data, with long-term follow-up and biospecimen collection (serum) stored in the hospital's biobank.
Receives: Other: observational study

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Systolic and Diastolic Blood Pressure

    Blood pressure will be measured using a standardized mercury sphygmomanometer after at least 5 minutes of rest in a seated position. Both systolic blood pressure (SBP) and diastolic blood pressure (DBP) will be recorded.

    Measured: through study completion, an average of 3 year

  2. Fasting Lipid Profile (Total Cholesterol, Triglycerides, LDL-C, and HDL-C)

    Venous blood samples will be collected after at least 8 hours of overnight fasting. Serum levels of total cholesterol (TC), triglycerides (TG), low-density lipoprotein cholesterol (LDL-C), and high-density lipoprotein cholesterol (HDL-C) will be measured using an automated biochemical analyzer at the central laboratory of Peking University Third Hospital.

    Measured: through study completion, an average of 3 year

  3. Fasting Blood Glucose (FBG)

    Fasting venous blood samples will be collected after at least 8 hours of overnight fasting. Serum glucose levels will be measured using an automated biochemical analyzer at the central laboratory of Peking University Third Hospital.

    Measured: through study completion, an average of 3 year

  4. Glycated Hemoglobin (HbA1c)

    Fasting venous blood samples will be collected and analyzed using high-performance liquid chromatography (HPLC) at the central laboratory of Peking University Third Hospital. HbA1c reflects average blood glucose levels over the previous 2 to 3 months.

    Measured: through study completion, an average of 3 year

  5. Complete Blood Count (CBC)

    Fasting venous blood samples will be collected and analyzed using an automated hematology analyzer at the central laboratory of Peking University Third Hospital. Key parameters include white blood cell count (WBC), red blood cell count (RBC), hemoglobin (HGB), hematocrit (HCT), mean corpuscular volume (MCV), mean corpuscular hemoglobin (MCH), mean corpuscular hemoglobin concentration (MCHC), and platelet count (PLT).

    Measured: through study completion, an average of 3 year

  6. Routine Urinalysis

    Midstream clean-catch urine specimens will be collected and analyzed using an automated urine analyzer and microscopy at the central laboratory of Peking University Third Hospital. Key parameters include urine specific gravity, pH, protein, glucose, ketones, bilirubin, urobilinogen, nitrite, leukocyte esterase, and microscopic examination of red blood cells, white blood cells, and casts.

    Measured: through study completion, an average of 3 year

  7. Liver Function Panel

    Fasting venous blood samples will be collected and analyzed using an automated biochemical analyzer at the central laboratory of Peking University Third Hospital. Key parameters include alanine aminotransferase (ALT), aspartate aminotransferase (AST), alkaline phosphatase (ALP), gamma-glutamyl transferase (GGT), total bilirubin (TBIL), direct bilirubin (DBIL), total protein (TP), and albumin (ALB).

    Measured: through study completion, an average of 3 year

  8. Renal Function Panel

    Fasting venous blood samples will be collected and analyzed using an automated biochemical analyzer at the central laboratory of Peking University Third Hospital. Key parameters include serum creatinine (Cr), blood urea nitrogen (BUN), uric acid (UA), and estimated glomerular filtration rate (eGFR) calculated using the CKD-EPI or MDRD equation.

    Measured: through study completion, an average of 3 year

  9. Pulmonary Assessment

    Chest X-ray or low-dose chest CT will be performed according to standardized protocols at the Radiology Department of Peking University Third Hospital. Findings will be interpreted by certified radiologists. Results will be reported as presence or absence of pulmonary abnormalities (e.g., nodules, infiltrates, or other clinically significant findings).

    Measured: through study completion, an average of 3 year

  10. Abdominal Ultrasound Assessment

    Abdominal ultrasound will be performed according to standardized protocols at the Radiology Department of Peking University Third Hospital for evaluation of the liver, gallbladder, pancreas, spleen, and kidneys. Findings will be interpreted by certified radiologists. Results will be reported as presence or absence of abnormalities in each organ.

    Measured: through study completion, an average of 3 year

  11. Carotid Artery Ultrasound Assessment

    Carotid artery ultrasound will be performed according to standardized protocols at the Radiology Department of Peking University Third Hospital for assessment of carotid intima-media thickness (CIMT) and plaque detection. CIMT will be measured in millimeters (mm). Plaque will be reported as present or absent. All findings will be interpreted by certified radiologists.

    Measured: through study completion, an average of 3 year

Secondary outcomes (8)
  1. BMI

    Body composition will be measured using bioelectrical impedance analysis (BIA) or dual-energy X-ray absorptiometry (DXA) at the Physical Examination Center of Peking University Third Hospital. Body mass index (BMI) will be calculated as weight in kilograms divided by height in meters squared (kg/m²).

    Measured: through study completion, an average of 3 year

  2. Body Fat Percentage

    Body composition will be measured using bioelectrical impedance analysis (BIA) or dual-energy X-ray absorptiometry (DXA) at the Physical Examination Center of Peking University Third Hospital. Body fat percentage (BFP) will be reported as a percentage (%).

    Measured: through study completion, an average of 3 year

  3. Visceral Fat Area

    Body composition will be measured using bioelectrical impedance analysis (BIA) or dual-energy X-ray absorptiometry (DXA) at the Physical Examination Center of Peking University Third Hospital. Visceral fat area (VFA) will be reported in square centimeters (cm²).

    Measured: through study completion, an average of 3 year

  4. Skeletal Muscle Mass

    Body composition will be measured using bioelectrical impedance analysis (BIA) or dual-energy X-ray absorptiometry (DXA) at the Physical Examination Center of Peking University Third Hospital. Skeletal muscle mass (SMM) will be reported in kilograms (kg).

    Measured: through study completion, an average of 3 year

  5. Handgrip Strength

    Physical fitness will be assessed by trained exercise physiologists at the Physical Examination Center of Peking University Third Hospital using standardized protocols. Handgrip strength will be measured using a handheld dynamometer and reported in kilograms (kg).

    Measured: through study completion, an average of 3 year

  6. Back Strength

    Back strength will be assessed by trained exercise physiologists at the Physical Examination Center of Peking University Third Hospital using a back dynamometer following standardized protocols. Results will be measured and reported in kilograms (kg).

    Measured: through study completion, an average of 3 year

  7. Vertical Jump Height

    Vertical jump height will be assessed by trained exercise physiologists at the Physical Examination Center of Peking University Third Hospital using a force platform or jump mat following standardized protocols. Results will be measured and reported in centimeters (cm).

    Measured: through study completion, an average of 3 year

  8. Estimated VO₂max

    Cardiorespiratory function will be assessed by trained exercise physiologists at the Physical Examination Center of Peking University Third Hospital using standardized protocols. Estimated maximal oxygen uptake (VO₂max) will be calculated and reported in milliliters per kilogram per minute (ml/kg/min).

    Measured: through study completion, an average of 3 year

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted12 Aug 2026
  2. Study start21 Feb 2025
  3. Primary completion31 Dec 2027 (estimated)
  4. Study completion31 Dec 2027 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Observational
Observational model
Cohort
Time perspective
Other
Enrolment
100,000 participants (estimated)
Target duration
3 Years
IDs, dates and publications
ClinicalTrials.gov ID
NCT07761676
Sponsor's protocol ID
BYSYDL2024010
Other IDs
IRB00006761-M20250131
Status last verified
Jul 2026
First submitted
16 Jul 2026
Last updated
12 Aug 2026
Results posted
No
Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
No

Questions about this trial

What is this clinical trial studying?

An observational study of Multiple Chronic Conditions (Unspecified) and Large-scale Health Examination Cohort, run by Peking University Third Hospital at 1 site in China.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 1 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: looking for participants now, as of the sponsor's last update on 12 Aug 2026. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in China. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

This study is still under way. Results are not available in the source record yet.

How can a doctor refer a patient or contact the research team?

Contact Liyuan Tao, PhD (+86 13581552613, tendytly@163.com), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Systolic and Diastolic Blood Pressure (time frame: through study completion, an average of 3 year). The study lists 11 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 12 Aug 2026.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in